KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Capital Expenditures (2017 - 2025)

Historic Capital Expenditures for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $12.3 million.

  • Amneal Pharmaceuticals' Capital Expenditures fell 2742.4% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.4 million, marking a year-over-year increase of 3604.88%. This contributed to the annual value of $51.9 million for FY2024, which is 2014.99% up from last year.
  • As of Q3 2025, Amneal Pharmaceuticals' Capital Expenditures stood at $12.3 million, which was down 2742.4% from $22.8 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Capital Expenditures ranged from a high of $22.8 million in Q2 2025 and a low of $5.0 million during Q2 2022
  • For the 5-year period, Amneal Pharmaceuticals' Capital Expenditures averaged around $12.5 million, with its median value being $11.7 million (2023).
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Capital Expenditures tumbled by 4075.1% in 2021, and later surged by 13773.02% in 2023.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Capital Expenditures stood at $17.5 million in 2021, then tumbled by 34.47% to $11.5 million in 2022, then dropped by 13.96% to $9.9 million in 2023, then surged by 53.62% to $15.2 million in 2024, then dropped by 18.85% to $12.3 million in 2025.
  • Its last three reported values are $12.3 million in Q3 2025, $22.8 million for Q2 2025, and $13.2 million during Q1 2025.